Lifesci Capital Stock Recommendations and Price Targets

This is a list of recent ratings by Lifesci Capital.

DateCompany NameActionCurrent
Price
Price
Target
RatingImpact on
Share Price
11/17/2021
NNOX
Nano-X Imaging
Downgrade$20.00Outperform ➝ Market PerformLow
11/15/2021
VTYX
Ventyx Biosciences
Reiterated Rating$22.00OutperformHigh
11/5/2021
AGLE
Aeglea BioTherapeutics
Reiterated Rating$6.00OutperformLow
11/4/2021
ALXO
ALX Oncology
Reiterated Rating$34.00OutperformMedium
11/2/2021
PYXS
Pyxis Oncology
Reiterated Rating$13.00OutperformLow
10/24/2021
RCKT
Rocket Pharmaceuticals
Reiterated Rating$24.00OutperformLow
8/26/2021
DRIO
DarioHealth
Reiterated Rating$16.00OutperformHigh
8/24/2021
VRDN
Viridian Therapeutics
Reiterated Rating$18.00OutperformLow
8/13/2021
LHDX
Lucira Health
Downgrade$7.00Outperform ➝ Market PerformMedium
8/4/2021
LRMR
Larimar Therapeutics
Reiterated Rating$10.00OutperformMedium
6/21/2021
OLMA
Olema Pharmaceuticals
Reiterated Rating$21.00OutperformHigh
6/3/2021
NNOX
Nano-X Imaging
Reiterated Rating$20.00OutperformHigh
5/4/2021
VECT
VectivBio
Reiterated Rating$4.00OutperformHigh
4/29/2021
ADVM
Adverum Biotechnologies
Downgrade$2.00Outperform ➝ Market PerformHigh
3/22/2021
ODT
Odonate Therapeutics
Downgrade$2.00Outperform ➝ Market PerformHigh
3/18/2021
ELDN
Eledon Pharmaceuticals
Reiterated Rating$5.00OutperformHigh
3/2/2021
LHDX
Lucira Health
Reiterated Rating$7.00OutperformHigh
1/4/2021
COGT
Cogent Biosciences
Reiterated Rating$8.00OutperformN/A
11/17/2020
CLDX
Celldex Therapeutics
Reiterated Rating$40.00OutperformHigh
11/12/2020
BLU
BELLUS Health
Reiterated Rating$5.00OutperformMedium
11/12/2020
BLU
BELLUS Health
Reiterated RatingC$7.00OutperformN/A
11/10/2020
TARS
Tarsus Pharmaceuticals
Reiterated Rating$25.00OutperformMedium
11/9/2020
AVDL
Avadel Pharmaceuticals
Reiterated Rating$10.00OutperformLow
11/6/2020
SRRA
Sierra Oncology
Reiterated Rating$23.00OutperformLow
11/5/2020
ADVM
Adverum Biotechnologies
Reiterated Rating$2.00OutperformMedium
11/5/2020
CBIO
Catalyst Biosciences
Reiterated Rating$1.00OutperformHigh
10/30/2020
IFRX
InflaRx
Reiterated Rating$5.00Market PerformLow
10/28/2020
ODT
Odonate Therapeutics
Reiterated Rating$2.00OutperformLow
10/27/2020
OYST
Oyster Point Pharma
Reiterated Rating$11.00OutperformMedium
10/23/2020
AGLE
Aeglea BioTherapeutics
Reiterated Rating$6.00OutperformMedium
10/22/2020
ALLK
Allakos
Reiterated Rating$80.00OutperformLow
10/21/2020
MEIP
MEI Pharma
Reiterated Rating$3.00OutperformMedium
10/16/2020
RCKT
Rocket Pharmaceuticals
Reiterated Rating$24.00OutperformLow
10/15/2020
INBX
Inhibrx
Reiterated Rating$38.00OutperformMedium
10/6/2020
IMVT
Immunovant
Reiterated Rating$8.00OutperformHigh
10/2/2020
VYNE
VYNE Therapeutics
Reiterated Rating$1.00OutperformHigh
9/30/2020
ALXO
ALX Oncology
Reiterated Rating$34.00OutperformLow
9/29/2020
CBAY
CymaBay Therapeutics
Reiterated Rating$4.00OutperformMedium
9/24/2020
CRTX
Cortexyme
Reiterated Rating$12.00OutperformHigh